Kineticos Life Sciences Partners with Orthobond
Kineticos Life Sciences has revealed an exciting new partnership with Orthobond, a leader in advanced antibacterial technologies. This collaboration is made possible through the Kineticos AMR Accelerator Fund I, which is actively working to support innovations in healthcare. Kineticos is eager to make a meaningful contribution to the fight against antimicrobial resistance, a growing global health issue.
Orthobond’s Investment and Growth
Orthobond has just received FDA approval for their De Novo application associated with their cutting-edge technology, Ostaguard™, which offers an antibacterial, non-drug eluting solution for spinal implants. This significant milestone showcases Orthobond’s dedication to improving patient safety during surgical procedures. With financial support from Kineticos, Orthobond is set to prepare for the commercialization of Ostaguard™ and broaden its application to areas beyond spinal surgery.
Pioneering Innovation in Healthcare
The diligent work of Orthobond in creating antibacterial surfaces for medical devices marks an important advancement in reducing bacterial infections in surgical environments. Mark Bamforth, part of the KAMRA Fund I General Partnership, voiced his excitement about collaborating with Orthobond. He underscored the importance of tackling bacterial contamination during implant surgeries, ultimately benefiting patients around the globe.
Perspectives from Orthobond’s Management
David Nichols, the CEO of Orthobond, expressed his enthusiasm for the partnership with Kineticos. He pointed out the potential for Ostaguard™ to establish itself as the gold standard for implantable devices, offering a safer alternative for patients. The insights and direction from Kineticos will be crucial as Orthobond continues to explore research and build a solid case for Ostaguard™.
Strategic Advisory Position
In a significant addition to this partnership, Steve Favaloro, Strategic Advisor to the KAMRA Fund I, will be joining the board of directors at Orthobond. With a wealth of experience in the biotech field, Favaloro emphasizes how Orthobond’s technology could greatly impact public health. His knowledge will help shape the company's growth and its efforts to combat antimicrobial resistance globally.
About Kineticos Life Sciences
Kineticos Life Sciences is committed to creating A World Without AMR™. By partnering with innovative entrepreneurs in the life sciences sector, Kineticos drives creativity aimed at tackling major medical challenges. Their investment in Orthobond illustrates their dedication to improving patient outcomes and pushing the limits of how diseases can be treated.
Looking Ahead with Orthobond
Orthobond Corporation is making progress in surface technology by developing proprietary antibacterial surfaces suitable for a wide range of industries, including medical devices, automotive, and beyond. Their innovative method of permanently binding antibacterial technologies has the potential to transform infection control, ensuring better health results for patients in various environments.
Frequently Asked Questions
What is the focus of the partnership between Kineticos and Orthobond?
The partnership centers on advancing innovative antibacterial technologies specifically for medical devices to help address antimicrobial resistance.
What technology has Orthobond introduced?
Orthobond has introduced Ostaguard™, an antibacterial non-drug eluting solution tailored for spinal implants, which recently gained FDA approval.
Who will be joining Orthobond's board of directors?
Steve Favaloro, the Strategic Advisor to the KAMRA Fund I, will be joining the board at Orthobond, contributing valuable insights from his biotech background.
How does Kineticos intend to influence healthcare?
Kineticos aims to revolutionize conventional approaches in drug development and disease diagnosis, seeking to improve patient outcomes everywhere.
What distinguishes Orthobond's technology?
Orthobond employs proprietary antibacterial surfaces that eliminate bacteria naturally, without relying on eluting antibiotics, thus offering a unique solution for infection prevention.
